You are here: Industry Insights > MS

News List

Eating Fish May Be Tied to a Reduced Risk of MS biospace
March 05, 2018
According to a preliminary study released today, consuming fish at least once weekly or 1-3 times a month may reduce the risk of multiple sclerosis (MS), except daily intake of fish oil supplements
NICE recommends routine access to beta interferon drug for MS europeanpharmaceuticalreview
December 22, 2017
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
Sanofi pays $40M, commits $765M more for preclinical MS drug fiercebiotech
November 10, 2017
Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma.
Breakthrough study could revolutionise MS treatment pharmafile
October 16, 2017
The results of a study from the University of California, San Francisco will be welcomed with a certain excitement from all quarters, given that it seems to show the repair of myelin damaged by multiple sclerosis
Synthon’s generic version of Copaxone at 40mg receives European approval to treat MS pharmaceufical-technology
October 09, 2017
MS is an unpredictable, often disabling disease of the central nervous system that disturbs the flow of information within the brain, and between the brain and body.
After 7 years, EC grants approval for Merck KGaA’s MS drug pharmafile
August 28, 2017
Pharmacovigilance is a science of understanding drug safety through identification, assessment, and prevention of adverse drug reactions (ADRs).
Native mass spectrometry uesed to help drug discovery europeanpharmaceuticalreview
August 18, 2017
Mass spectrometry (MS) performed under native-like conditions (nMS) is a promising approach for studying protein-drug interactions, and has already informed treatments of some of the most intractable diseases including cancer, diabetes and Alzheimer’s.
Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS cphi-online
June 27, 2017
Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical trials.
Common treatment for MS revealed to have potential adverse reactions pharmafile
May 17, 2017
Beta interferons are a common treatment used to manage multiple sclerosis. The treatment works by reducing and preventing the inflammation that damages nerves in sufferers of MS, thus reducing the number of relapses in those with relapsing-remitting multi
MS Trusts names first sites for specialist nurse scheme pharmatimes
April 27, 2017
The MS Trust has announced that Leicester and Bradford are the first sites chosen for its multiple sclerosis specialist nurse...

Previous page 1 2 3 4 5 6 7 8 9 Next page